Nuochengjianhua announced that the Phase III registered clinical trial of the new-generation highly selective oral TYK2 inhibitor soficitinib independently developed by the company to treat adult patients with moderate to severe atopic dermatitis reached the main end point, was highly statistically significant, and achieved clinically significant improvements. A number of secondary endpoints were also successfully achieved. The safety results were consistent with previous studies, and no new safety signals were found. The company will continue to complete long-term safety follow-up and promote subsequent registration and reporting.

Nuochengjianhua announced that the Phase III registered clinical trial of the new-generation highly selective oral TYK2 inhibitor soficitinib independently developed by the company to treat adult patients with moderate to severe atopic dermatitis reached the main end point, was highly statistically significant, and achieved clinically significant improvements. A number of secondary endpoints were also successfully achieved. The safety results were consistent with previous studies, and no new safety signals were found. The company will continue to complete long-term safety follow-up and promote subsequent registration and reporting.